Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 1, 2015, Pages 78-84

  Zhang, Qing Qing ^a   Lu, Lun Gen ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Cardiovascular disease; Dyslipidemia; Hypolipidemic agents; Nonalcoholic fatty liver disease

Indexed keywords

EID: 84962112426     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00037     Document Type: Review

References (66)

1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524–530. doi: 10.1016/j.cgh.2011.03.020.
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe. A Review of available epidemiological data. J Hepatol 2013;58:593–608. doi: 10.1016/j.jhep.2012.12.005.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:2121–1231.
4. http://dx.doi.org/10.1787/9789264183896-en, accessed April 2014.
5. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepa-titis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131. doi: 10.1053/j.gastro.2010.09.038.
6. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohe-patitis in the United States. Gastroenterology 2011;141:1249–1253. doi: 10.1053/j.gastro.2011.06.061.
7. Scott C. Matherly, Puneet Puri. Mechanisms of Simple Hepatic Steatosis: Not So Simple After All. Clin Liver Dis 2012;16:505–524. doi: 10.1016/j.cld.2012.05.005.
8. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and manage-ment. Hepatology 2009;49:306–317. doi: 10.1002/hep.22603.
9. Dima A, Marinescu AG, Dima AC. Non-alcoholic fatty liver disease and the statins treatment. Rom J Intern Med 2012, 50:19–25.
10. Ji C, Dai Y, Jiang W, Liu J, Hou M, Wang J, et al. Postnatal overfeeding promotes early onset and exaggeration of high-fat diet-induced nonalcoholic fatty liver disease through disordered hepatic lipid metabolism in rats. J Nutr Biochem 2014;25: 1108–1116. doi: 10.1016/j.jnutbio.2014.06.010.
11. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913–924. doi: 10.1002/hep.23784.
12. Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013;61:448– 453.
13. Boyraz M, Hatipoğlu N, Sarı E, Akcay A, Taskin N, Ulucan K, et al. Nonalcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obes Res Clin Pract 2014;8:e356–e363. doi: 10.1016/j.orcp.2013.08.003.
14. Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014;15:493– 503. doi: 10.1517/14656566.2014.876992.
15. Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1724–1745. doi: 10.3748/wjg.v20.i7.1724.
16. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341–1350. doi: 10.1056/NEJMra0912063.
17. Souza MR, Diniz MF, Medeiros JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol 2012;49:89– 96.
18. Norris AL, Steinberger J, Steffen LM, Metzig AM, Schwarzenberg SJ, Kelly AS. Circulating oxidized LDL and inflammation in extreme pediatric obesity. Obesity 2011;19:1415–1419. doi: 10.1038/oby.2011.21.
19. Sahebkar A1, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother 2014, 15:493– 503. doi: 10.1517/14656566.2014.876992.
20. Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes 2010;4:129–137. doi: 10.1016/j.pcd.2010. 02.004.
21. Gawrieh S, Baye TM, Carless M, Wallace J, Komorowski R, Kleiner DE, et al. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes Surg 2010;20:1698–1709. doi: 10.1007/s11695-010-0171-6.
22. Alkhouri N, Eng K, Lopez R, Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD). Springerplus 2014;3:407. doi: 10.1186/2193-1801-3-407.
23. Cao W, Zhao C, Shen C, Wang Y. Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepa-titis. PLOS One 2013;8:e82092. doi: 10.1371/journal.pone.0082092.
24. Kampschulte M, Stockl C, Langheinrich AC, Althohn U, Bohle RM, Krombach GA, et al. Western diet in ApoE-LDLR double-deficient mouse model of atherosclerosis leads to hepatic steatosis, fibrosis, and tumorigenesis. Lab Invest 2014;94:1273–1282. doi: 10.1038/labinvest.2014.112.
25. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014, 164:312–322. doi: 10.1016/j.trsl.2014.06.008.
26. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221– 1231.
27. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010;51:1979–1987. doi: 10.1002/hep.23593.
28. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595–602. doi: 10.1002/hep.23314.
29. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873. doi: 10.1002/hep.21327.
30. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419. doi: 10.1016/S0016-5085(99)70506-8.
31. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234–238. doi: 10.1016/j.cgh.2008.11.005.
32. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol 2014;20:8407–8415. doi: 10.3748/wjg.v20.i26.8407.
33. Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544–1560. doi: 10.3390/nu5051544.
34. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25:567–579.
35. Managing your dyslipidemia with TLC: Therapeutic Lifestyle Changes. J Am Osteopath Assoc 2010, 110:eS17–eS18.
36. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2010;3:121–137. doi: 10.1177/1756283X09359964.
37. Fock KM, Khoo J. Diet and exercise in management of obesity and overweight. J Gastroenterol Hepatol 2013;28(Suppl):59–63. doi: 10.1111/jgh.12407.
38. St George A, Bauman A, Johnston A, Farrell G, Chey T, Georgr J. The independent effects of physical activity in patients with non-alcoholic fatty liver disease. Hepatology 2009;50:68–76. doi: 10.1002/hep.22940.
39. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol 2009;24:399–407. doi: 10.1111/j.1440-1746.2008.05694.x
40. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J, et al. One-year intense nutritional counseling results in histological improvement in patients with nonalcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072–1081. doi: 10.1111/j.1572-0241.2005.41334.x.
41. Grzegorzewska AE, Niepolski L, Sikora J, Jankow M, Jagodzinski PP, Sowinska A. Effect of lifestyle changes and atorvastatin administration on dyslipidemia in hemodialysis patients: a prospective study. Pol Arch Med Wewn 2014;124: 443–451.
42. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916–1922. doi: 10.1016/S0140-6736(10)61272-X.
43. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. J Clin Gastroenterol 2009;43:990–994. doi: 10.1097/MCG.0b013e31819c392e.
44. Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis 2006;184:233–234. doi: 10.1016/j.atherosclerosis.2005.08.021.
45. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193–196. doi: 10.1016/j.atherosclerosis.2004.01.008.
46. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088–2093. doi: 10.1161/01.CIR.98.19.2088.
47. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31: 384. doi: 10.1016/S0168-8278(99)80243-8.
48. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomized study. Curr Med Res Opin 2006;22:873–883. doi: 10.1185/030079906X104696.
49. Fernández-Miranda C, Pérez-Carreras M, Colina F, Lopez-Alonso G, Vargas C, Solis-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis 2008;40:200–205. doi: 10.1016/j.dld.2007. 10.002.
50. Davidson HM. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003;1:11–21. doi: 10.1586/14779072.1.1.11.
51. Weintraub H. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 2013; 230:381–389. doi: 10.1016/j.atherosclerosis.2013.07.041.
52. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacotherapy 2007;27:715–728. doi: 10.1592/phco.27.5.715.
53. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged omega-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006;23:1143–1151. doi: 10.1111/j.1365-2036.2006.02885.x.
54. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of omega-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008;40:194–199. doi: 10.1016/j.dld.2007.10.003.
55. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohe-patitis. J Clin Gastroenterol 2008;42:413–418. doi: 10.1097/MCG.0b013 e31815591aa.
56. Vega GL, Chandalia M, Szczepaniak LS, Grundy SM. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med 2008;56:780–785. doi: 10.231/JIM.0b013e318177024d.
57. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007;27:1918–1925. doi: 10.1161/ATVBAHA.106.136853.
58. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011;106: 71–77. doi: 10.1038/ajg.2010.299.
59. Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46: 1453–1463. doi: 10.1002/hep.21848.
60. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287–1292. doi: 10.1053/j.gastro.2004. 02.015.
61. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105:2341–2346. doi: 10.1161/01.CIR.0000017634.00171.24.
62. Mateen FJ, Kanters S, Kalyesubula R, Mukasa B, Kawuma E, Kengne AP, et al. Hypertension prevalence and Framingham risk score stratification in a large HIV-positive cohort in Uganda. J Hypertens 2013;31:1372–1378. doi: 10.1097/HJH.0b013e328360de1c.
63. Lavine JE, Schwimmer JB, Natta ML, Molleston JP, Murray KF, Rosenthal P. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659–1668. doi: 10.1001/jama.2011.520.
64. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372–384. doi: 10.1016/j.jhep.2010.04.008.
65. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohe-patitis. Am J Gastroenterol 2001;96:519–525. doi: 10.1111/j.1572-0241.2001.03553.x.
66. Musso G, Cassader G, Rosina F, Gambino F. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885–904. doi: 10.1007/s00125-011-2446-4.